Literature DB >> 17690696

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

D Heintel, N Zojer, M Schreder, K Strasser-Weippl, B Kainz, M Vesely, H Gisslinger, J Drach, A Gaiger, U Jäger, H Ludwig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17690696     DOI： 10.1038/sj.leu.2404895

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Genetic susceptibility variants for chronic lymphocytic leukemia.

Authors:  Susan L Slager; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Rassenti; Jose F Leis; Nicola J Camp; Neil E Kay; Celine M Vachon; Martha Glenn; J Brice Weinberg; Kari G Rabe; Julie M Cunningham; Sara J Achenbach; Curtis A Hanson; Gerald E Marti; Timothy G Call; Neil E Caporaso; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

2.  Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.

Authors:  Kazutaka Shimbo; Gerald W Hsu; Huy Nguyen; Sami Mahrus; Jonathan C Trinidad; Alma L Burlingame; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

3.  High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.

Authors:  Manuela Gambella; Alberto Rocci; Roberto Passera; Francesca Gay; Paola Omedè; Claudia Crippa; Paolo Corradini; Alessandra Romano; Davide Rossi; Marco Ladetto; Mario Boccadoro; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

4.  IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

Authors:  Shirong Li; Rekha Pal; Sara A Monaghan; Peter Schafer; Hongjiao Ouyang; Markus Mapara; Deborah L Galson; Suzanne Lentzsch
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

5.  C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.

Authors:  Rekha Pal; Martin Janz; Deborah L Galson; Margarete Gries; Shirong Li; Korinna Jöhrens; Ioannis Anagnostopoulos; Bernd Dörken; Markus Y Mapara; Lisa Borghesi; Lela Kardava; G David Roodman; Christine Milcarek; Suzanne Lentzsch
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

6.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

Review 7.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

8.  Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.

Authors:  Ashni A Vora; Phoebe K Mondala; Caitlin Costello; A Robert MacLeod; Leslie A Crews
Journal:  STAR Protoc       Date:  2021-05-27

9.  The IRF family of transcription factors: Inception, impact and implications in oncogenesis.

Authors:  Hideyuki Yanai; Hideo Negishi; Tadatsugu Taniguchi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.